3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
12
Gynecologic
2
Tumor-Agnostic
1
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
182
Magnetic Resonance Spectroscopy
161
Specimen Handling
134
enzalutamide
125
Nivolumab
118
Gemcitabine
96
Docetaxel
92
Radiosurgery
91
Prednisone
81
Androgen Antagonists
81
Abiraterone Acetate
79
Radiotherapy
75
apalutamide
66
Cisplatin
65
darolutamide
62
Ipilimumab
61
Biopsy
61
abiraterone
57
cabozantinib
55
Carboplatin
55
Leuprolide
52
enfortumab vedotin
50
Radiation
47
Pluvicto
45
Standard of Care
44
atezolizumab
41
Surveys and Questionnaires
38
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
37
X-Rays
37
avelumab
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
AZD9833
×
Genitourinary
×
1 year
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled